Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

Rigshospitalet

Status: Completed

Conditions: Neovascular Age-related Macular Degeneration

Treatments: Drug: Faricimab

Study type: Observational

Funder types: Other

Identifiers

NCT06124677

VAB1SHOT

Details and patient eligibility

About

The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD), who were previously treated with aflibercept (Eylea®) and had persisting intraretinal or subretinal fluid despite frequent treatments.

Enrollment: 46 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Presence of neovascular age-related macular degeneration (AMD) in the study eye
• >50 years of age
• Previous intravitreal anti-VEGF treatment with aflibercept (Eylea®) or with aflibercept and ranibizumab (Lucentis®) in the study eye
• Minimum of 6 monthly aflibercept injections
• Persisting intraretinal or subretinal fluid or both, despite at least 3 consecutive monthly aflibercept injections in the study eye before switching to faricimab

Exclusion criteria

• Neovascular conditions other than AMD (e.g., choroidal neovascularisation due to other causes) or co-existence of other retinal disease in the study eye
• Significant optical media opacities that would result in poor imaging quality on OCT scans in the study eye
• Intraocular surgery in the study eye 3 months before or within 1 month after the treatment switch

Trial design

46 participants in 1 patient group

Patients

Description:

Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.

Treatment:

Drug: Faricimab